CLYM Climb Bio, Inc.
$14.25▼ -4.68%
Healthcare
Other
After hours
$14.48▲ +1.61%
Sep 11, 7:30 PM ET
Volume 1.38M
Avg Volume (10D) 1.91M
Key Metrics & Fundamentals
Market Cap
$818.47M
P/E Ratio
–
Div Yield
–%
52W Range
1.54 - 18.33
% vs 50 MA
0.46%
% vs 200 MA
58.79%
RSI-14
45.8
MACD Histogram
-0.2300
Beta (1Y vs SPY)
1.85
Free Cash Flow
-$10.81M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$15.33M
COGS
–
Operating Exp
$15.36M
Operating Income
-$15.36M
EBIT
-$15.36M
Pretax Income
-$13.50M
Net Income
-$13.50M
EPS (Diluted)
-0.18
Price & Volume History
Loading chart…
Recent News
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating
MT Newswires · Sep 8, 2026 1:24 PM
Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says
MT Newswires · Sep 4, 2026 3:17 PM
B. Riley Adjusts Price Target on Climb Bio to $30 From $26, Maintains Buy Rating
MT Newswires · Sep 4, 2026 12:14 PM
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
BioPharma Dive · Sep 4, 2026 9:00 AM
Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble
Investor's Business Daily · Sep 3, 2026 8:51 PM
Update: Climb Bio Shares Fall After Early Phase 1 Data for IgA Nephropathy Drug
MT Newswires · Sep 3, 2026 6:18 PM
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
MarketBeat · Sep 3, 2026 6:02 PM
Wedbush Adjusts Price Target on Climb Bio to $25 From $20, Keeps Outperform Rating
MT Newswires · Sep 3, 2026 3:23 PM
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data
InvestorsHub · Sep 3, 2026 1:37 PM
Climb Bio Reports Early Phase 1 Data for IgA Nephropathy Drug
MT Newswires · Sep 3, 2026 11:54 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CLYM's money flow as a full page
Social Sentiment
Avg +0.70 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.